ONKOLOGIE / Onkologie. 2023;17(3):209-214 / www.onkologiecs.cz 214 ZAZNĚLO NA KONGRESE LÉČBA PACIENTŮ S MNOHOČETNÝM MYELOMEM PO EXPOZICI LENALIDOMIDU A POSTAVENÍ PŘÍPRAVKU NINLARO V TERAPEUTICKÉ SEKVENCI LITERATURA 1. Ninlaro. Ceny a úhrady. Dostupné na: www.prehledy.sukl.cz (navštíveno 31. 5. 2023). 2. Revlimid. Ceny a úhrady. www.prehledy.sukl.cz. 3. Jackson GH, Davies FE, Pawlyn C, et al. UK NCRI Haemato- -oncology Clinical Studies Group. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73. 4. Jackson GH, Pawlyn C, Cairns DA, et al. UK NCRI Haemato-oncology Clinical Studies Group. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2021;192(5):853-868. 5. Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):S43-S53. 6. Rajkumar SV, Harousseau JL, Durie B, et al. International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695. 7. Nijhof IS, van de Donk NWCJ, Zweegman S, et al. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs. 2018;78(1):19-37. 8. Orlowski RZ, Lonial S. Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clin Cancer Res. 2016;22(22):5443-5452. 9. Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23(9):2789-2797. 10. Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301-308. 11. Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood. 2012;120(5):927-928. 12. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. 13. Brioli A, Melchor L, Cavo M, et al. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165(4):441-454. 14. Dimopoulos MA, Richardson P, Lonial S. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(7):460-473. 15. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere. 2021;5(2):e528. 16. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):508-517. 17. Dimopoulos MA, Moreau P, Terpos E, et al. EHA Guidelines Committee. ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309-322. 18. Kunacheewa C, Feng L, Manasanch EE, et al. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol. 2021;193(3):e23-e26. 19. Moreau P, Masszi T, Grzasko N, et al. TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):16211634. 20. Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide- -dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102(10):1767-1775. 21. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib- -lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7(4):e554. 22. Dimopoulos MA, Oriol A, Nahi H, et al. POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319-1331. 23. Richardson PG, Jagannath S, Moreau P, et al. 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open- -label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516-527. 24. Lee HC, Ramasamy K, Marco M, et al. Impact of prior treatment exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients treated in routine clinical practice (the INSURE study). HemaSphere. Juna 2022;6:815-816. Řešením je ELEKTRONICKÉ PŘEDPLATNÉ Chcete číst aktuální články časopisu ONKOLOGIEON-LINE? ◼ www.onkologiecs.cz ČTĚTE IHNEDv podobě listovačky či ve formátu PDF ◼ bez přihlášení/předplatného jsou články přístupné až po 1 roce ◼ 5 čísel/rok – 660 Kč (vč. tematických příloh) Objednávejte v našem e-shopu➜ www.solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=